Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2017 4
2018 3
2019 5
2020 8
2021 6
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting.
Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Vidal GA, et al. JCO Oncol Pract. 2024 Mar;20(3):370-377. doi: 10.1200/OP.23.00253. Epub 2024 Jan 9. JCO Oncol Pract. 2024. PMID: 38194619
Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.
Anderson JN, Paladino AJ, Blue R, Dangerfield DT 2nd, Eggly S, Martin MY, Schwartzberg LS, Vidal GA, Graetz I. Anderson JN, et al. Among authors: vidal ga. J Cancer Surviv. 2023 Dec 19. doi: 10.1007/s11764-023-01511-0. Online ahead of print. J Cancer Surviv. 2023. PMID: 38114711
Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research.
Vidal GA, Chalela P, Curry AN, El-Rayes B, Halmos B, Herrera AF, Kapoor KG, Kaur S, Mahadevan D, Mesa R, Ramirez A, Sleckman B, Wagner AL, Bhagat R, Brown I, Cruz L, Funwie A, Highsmith Q, Richie N, McKenzie M. Vidal GA, et al. Contemp Clin Trials. 2024 Feb;137:107416. doi: 10.1016/j.cct.2023.107416. Epub 2023 Dec 16. Contemp Clin Trials. 2024. PMID: 38109966 Free article.
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam LH, Jones S, Reilly SJ, Huang X, Shah K, Dent R. Schmid P, et al. Among authors: vidal ga. Clin Cancer Res. 2024 Feb 16;30(4):767-778. doi: 10.1158/1078-0432.CCR-23-2084. Clin Cancer Res. 2024. PMID: 38060199 Free PMC article. Clinical Trial.
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Elias AD, et al. Among authors: vidal ga. NPJ Breast Cancer. 2023 May 20;9(1):41. doi: 10.1038/s41523-023-00544-z. NPJ Breast Cancer. 2023. PMID: 37210417 Free PMC article.
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.
Saltman DL, Varga MG, Nielsen TJ, Croteau NS, Lockyer HM, Jain AL, Vidal GA, Hout DR, Schweitzer BL, Seitz RS, Ross DT, Gandara DR. Saltman DL, et al. Among authors: vidal ga. Clin Lung Cancer. 2023 Mar;24(2):137-144. doi: 10.1016/j.cllc.2022.11.009. Epub 2022 Dec 5. Clin Lung Cancer. 2023. PMID: 36564297 Free article.
47 results